ALK and neoplasm: The MPR and pCR rates increased to 41.2% (7/17; 95% CI 18.4–67.1%) and 23.5% (4/17; 95% CI 6.8–49.9%), respectively, when patients with known tumor EGFR mutations and ALK rearrangements (EGFR/ALK alterations) were excluded in the Nivo+CT arm (Fig. 2c and Supplementary Table 5).